Globalpharma, a leading generics manufacturer in the UAE and a wholly owned subsidiary of Dubai Investments PJSC, has reduced its carbon footprint by approximately 11,400 tonnes of CO₂ through the installation of a 612 kWp (kilowatt-peak) rooftop solar photovoltaic (PV) system at its
GlobalPharma
Globalpharma, a wholly owned subsidiary of Dubai Investments and one of the UAE’s leading pharmaceutical manufacturers, has signed seven strategic Memorandums of Understanding (MoUs) with leading partners to strengthen its capabilities across research and development, manufacturing optimisation, financing and sustainable operations. The collaborations are structured across
Globalpharma, the UAE’s leading pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments PJSC, today announced a significant milestone by capturing a 1.8% market share in the competitive Saudi pharmaceutical landscape. As of May 2024, Globalpharma’s sales surged by 139.5% year-over-year, reaching $12.6 million up from $5.2 million in the same period












